Patents by Inventor Colin Stephen MAGOWAN

Colin Stephen MAGOWAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME
    Publication number: 20240091347
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Application
    Filed: October 24, 2023
    Publication date: March 21, 2024
    Inventors: Hildegund CJ ERTL, Colin Stephen MAGOWAN
  • Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
    Patent number: 11850282
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: December 26, 2023
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan
  • ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME
    Publication number: 20230063089
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 2, 2023
    Inventors: Hildegund CJ ERTL, Colin Stephen MAGOWAN
  • ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME
    Publication number: 20220175913
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Inventors: Hildegund CJ ERTL, Colin Stephen MAGOWAN
  • Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
    Patent number: 11291716
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: April 5, 2022
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan
  • ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME
    Publication number: 20210393770
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 23, 2021
    Inventors: Hildegund CJ ERTL, Colin Stephen MAGOWAN